Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1
Thirty‐nine tumor‐bearing patients with metastatic melanoma were treated with 3 subcutaneous injections of the MAGE‐3.A1 peptide at monthly intervals. No significant toxicity was observed. Of the 25 patients who received the complete treatment, 7 displayed significant tumor regressions. All but one...
Gespeichert in:
| Veröffentlicht in: | International journal of cancer 1999-01, Vol.80 (2), p.219-230 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 230 |
|---|---|
| container_issue | 2 |
| container_start_page | 219 |
| container_title | International journal of cancer |
| container_volume | 80 |
| creator | Marchand, Marie van Baren, Nicolas Weynants, Patrick Brichard, Vincent Dréno, Brigitte Tessier, Marie‐Hélène Rankin, Elaine Parmiani, Giorgio Arienti, Flavio Humblet, Yves Bourlond, André Vanwijck, Romain Liénard, Danielle Beauduin, Marc Dietrich, Pierre‐Yves Russo, Vincenzo Kerger, Joseph Masucci, Giuseppe Jäger, Elke De Greve, Jacques Atzpodien, Jens Brasseur, Francis Coulie, Pierre G. van der Bruggen, Pierre Boon, Thierry |
| description | Thirty‐nine tumor‐bearing patients with metastatic melanoma were treated with 3 subcutaneous injections of the MAGE‐3.A1 peptide at monthly intervals. No significant toxicity was observed. Of the 25 patients who received the complete treatment, 7 displayed significant tumor regressions. All but one of these regressions involved cutaneous metastases. Three regressions were complete and 2 of these led to a disease‐free state, which persisted for more than 2 years after the beginning of treatment. No evidence for a cytolytic T lymphocyte (CTL) response was found in the blood of the 4 patients who were analyzed, including 2 who displayed complete tumor regression. Our results suggest that injection of the MAGE‐3.A1 peptide induced tumor regression in a significant number of the patients, even though no massive CTL response was produced. Int. J. Cancer 80:219–230, 1999. © 1999 Wiley‐Liss, Inc. |
| doi_str_mv | 10.1002/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.0.CO;2-S |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_17228030</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17228030</sourcerecordid><originalsourceid>FETCH-LOGICAL-p3470-acc369c8ae2f29afa40e7c8648b67c3c11d8a97ca42715c988222d5b266ec6493</originalsourceid><addsrcrecordid>eNpFkctuEzEUhkcIVELhEZC8QKhdTDi252IHBBoNpR0UlEWKxM5yPCfFaG6MHarseAQWPCFPgqcJRbJk6_yfz5H9RdE7CnMKwF6drauyOqcg8xgYTc-olBIoFecCFuwNo3KxKKr3cfWxpPCWz2Ferl6zeP0gmt3feRjNQieIc8qzx9ET575B6JBCchKdSMlTBnwW_b7etf1IRrwZ0Tnbd470G4fjD6yJ7cigvcXOO3Jr_VfSotfOh5IJx0Z3fauJH1H7AN8BugvL2xvsAjLg4G2NBDvT14HY7EkIkHwqLi_-_PzFA1qTIYwNAw7x1bIIQUGfRo-2unH47LifRp8_XFyXV_FydVmVxTIeeJJDrI3hmTRCI9syqbc6AcyNyBKxyXLDDaW10DI3OmE5TY0UgjFWpxuWZWiyRPLT6OWh7zD233fovGqtM9iEp2G_c4rmjAngEMDnR3C3abFWw2hbPe7V8RtD_uKYa2d0sx11Z6y7x2hGOWNTmy8H7NY2uP8fg5qcq0m5mvSpSZ_6p1wJUEwF5SoYV3fGFVegylUorw8F_heQeqZn</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17228030</pqid></control><display><type>article</type><title>Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Marchand, Marie ; van Baren, Nicolas ; Weynants, Patrick ; Brichard, Vincent ; Dréno, Brigitte ; Tessier, Marie‐Hélène ; Rankin, Elaine ; Parmiani, Giorgio ; Arienti, Flavio ; Humblet, Yves ; Bourlond, André ; Vanwijck, Romain ; Liénard, Danielle ; Beauduin, Marc ; Dietrich, Pierre‐Yves ; Russo, Vincenzo ; Kerger, Joseph ; Masucci, Giuseppe ; Jäger, Elke ; De Greve, Jacques ; Atzpodien, Jens ; Brasseur, Francis ; Coulie, Pierre G. ; van der Bruggen, Pierre ; Boon, Thierry</creator><creatorcontrib>Marchand, Marie ; van Baren, Nicolas ; Weynants, Patrick ; Brichard, Vincent ; Dréno, Brigitte ; Tessier, Marie‐Hélène ; Rankin, Elaine ; Parmiani, Giorgio ; Arienti, Flavio ; Humblet, Yves ; Bourlond, André ; Vanwijck, Romain ; Liénard, Danielle ; Beauduin, Marc ; Dietrich, Pierre‐Yves ; Russo, Vincenzo ; Kerger, Joseph ; Masucci, Giuseppe ; Jäger, Elke ; De Greve, Jacques ; Atzpodien, Jens ; Brasseur, Francis ; Coulie, Pierre G. ; van der Bruggen, Pierre ; Boon, Thierry</creatorcontrib><description>Thirty‐nine tumor‐bearing patients with metastatic melanoma were treated with 3 subcutaneous injections of the MAGE‐3.A1 peptide at monthly intervals. No significant toxicity was observed. Of the 25 patients who received the complete treatment, 7 displayed significant tumor regressions. All but one of these regressions involved cutaneous metastases. Three regressions were complete and 2 of these led to a disease‐free state, which persisted for more than 2 years after the beginning of treatment. No evidence for a cytolytic T lymphocyte (CTL) response was found in the blood of the 4 patients who were analyzed, including 2 who displayed complete tumor regression. Our results suggest that injection of the MAGE‐3.A1 peptide induced tumor regression in a significant number of the patients, even though no massive CTL response was produced. Int. J. Cancer 80:219–230, 1999. © 1999 Wiley‐Liss, Inc.</description><identifier>ISSN: 0020-7136</identifier><identifier>EISSN: 1097-0215</identifier><identifier>DOI: 10.1002/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.0.CO;2-S</identifier><identifier>PMID: 9935203</identifier><identifier>CODEN: IJCNAW</identifier><language>eng</language><publisher>New York: John Wiley & Sons, Inc</publisher><subject>Adult ; Aged ; Antigen Presentation ; Antigens, Neoplasm - adverse effects ; Antigens, Neoplasm - genetics ; Antigens, Neoplasm - therapeutic use ; Antineoplastic agents ; Biological and medical sciences ; Disease Progression ; Female ; Genetic Code ; HLA-A1 Antigen - immunology ; Humans ; Immunotherapy ; Male ; Medical sciences ; Melanoma - secondary ; Melanoma - therapy ; Middle Aged ; Neoplasm Proteins - adverse effects ; Neoplasm Proteins - genetics ; Neoplasm Proteins - therapeutic use ; Pharmacology. Drug treatments ; Remission Induction - methods</subject><ispartof>International journal of cancer, 1999-01, Vol.80 (2), p.219-230</ispartof><rights>Copyright © 1999 Wiley‐Liss, Inc.</rights><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2F%28SICI%291097-0215%2819990118%2980%3A2%3C219%3A%3AAID-IJC10%3E3.0.CO%3B2-S$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2F%28SICI%291097-0215%2819990118%2980%3A2%3C219%3A%3AAID-IJC10%3E3.0.CO%3B2-S$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1613220$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9935203$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Marchand, Marie</creatorcontrib><creatorcontrib>van Baren, Nicolas</creatorcontrib><creatorcontrib>Weynants, Patrick</creatorcontrib><creatorcontrib>Brichard, Vincent</creatorcontrib><creatorcontrib>Dréno, Brigitte</creatorcontrib><creatorcontrib>Tessier, Marie‐Hélène</creatorcontrib><creatorcontrib>Rankin, Elaine</creatorcontrib><creatorcontrib>Parmiani, Giorgio</creatorcontrib><creatorcontrib>Arienti, Flavio</creatorcontrib><creatorcontrib>Humblet, Yves</creatorcontrib><creatorcontrib>Bourlond, André</creatorcontrib><creatorcontrib>Vanwijck, Romain</creatorcontrib><creatorcontrib>Liénard, Danielle</creatorcontrib><creatorcontrib>Beauduin, Marc</creatorcontrib><creatorcontrib>Dietrich, Pierre‐Yves</creatorcontrib><creatorcontrib>Russo, Vincenzo</creatorcontrib><creatorcontrib>Kerger, Joseph</creatorcontrib><creatorcontrib>Masucci, Giuseppe</creatorcontrib><creatorcontrib>Jäger, Elke</creatorcontrib><creatorcontrib>De Greve, Jacques</creatorcontrib><creatorcontrib>Atzpodien, Jens</creatorcontrib><creatorcontrib>Brasseur, Francis</creatorcontrib><creatorcontrib>Coulie, Pierre G.</creatorcontrib><creatorcontrib>van der Bruggen, Pierre</creatorcontrib><creatorcontrib>Boon, Thierry</creatorcontrib><title>Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1</title><title>International journal of cancer</title><addtitle>Int J Cancer</addtitle><description>Thirty‐nine tumor‐bearing patients with metastatic melanoma were treated with 3 subcutaneous injections of the MAGE‐3.A1 peptide at monthly intervals. No significant toxicity was observed. Of the 25 patients who received the complete treatment, 7 displayed significant tumor regressions. All but one of these regressions involved cutaneous metastases. Three regressions were complete and 2 of these led to a disease‐free state, which persisted for more than 2 years after the beginning of treatment. No evidence for a cytolytic T lymphocyte (CTL) response was found in the blood of the 4 patients who were analyzed, including 2 who displayed complete tumor regression. Our results suggest that injection of the MAGE‐3.A1 peptide induced tumor regression in a significant number of the patients, even though no massive CTL response was produced. Int. J. Cancer 80:219–230, 1999. © 1999 Wiley‐Liss, Inc.</description><subject>Adult</subject><subject>Aged</subject><subject>Antigen Presentation</subject><subject>Antigens, Neoplasm - adverse effects</subject><subject>Antigens, Neoplasm - genetics</subject><subject>Antigens, Neoplasm - therapeutic use</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Genetic Code</subject><subject>HLA-A1 Antigen - immunology</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Melanoma - secondary</subject><subject>Melanoma - therapy</subject><subject>Middle Aged</subject><subject>Neoplasm Proteins - adverse effects</subject><subject>Neoplasm Proteins - genetics</subject><subject>Neoplasm Proteins - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Remission Induction - methods</subject><issn>0020-7136</issn><issn>1097-0215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkctuEzEUhkcIVELhEZC8QKhdTDi252IHBBoNpR0UlEWKxM5yPCfFaG6MHarseAQWPCFPgqcJRbJk6_yfz5H9RdE7CnMKwF6drauyOqcg8xgYTc-olBIoFecCFuwNo3KxKKr3cfWxpPCWz2Ferl6zeP0gmt3feRjNQieIc8qzx9ET575B6JBCchKdSMlTBnwW_b7etf1IRrwZ0Tnbd470G4fjD6yJ7cigvcXOO3Jr_VfSotfOh5IJx0Z3fauJH1H7AN8BugvL2xvsAjLg4G2NBDvT14HY7EkIkHwqLi_-_PzFA1qTIYwNAw7x1bIIQUGfRo-2unH47LifRp8_XFyXV_FydVmVxTIeeJJDrI3hmTRCI9syqbc6AcyNyBKxyXLDDaW10DI3OmE5TY0UgjFWpxuWZWiyRPLT6OWh7zD233fovGqtM9iEp2G_c4rmjAngEMDnR3C3abFWw2hbPe7V8RtD_uKYa2d0sx11Z6y7x2hGOWNTmy8H7NY2uP8fg5qcq0m5mvSpSZ_6p1wJUEwF5SoYV3fGFVegylUorw8F_heQeqZn</recordid><startdate>19990118</startdate><enddate>19990118</enddate><creator>Marchand, Marie</creator><creator>van Baren, Nicolas</creator><creator>Weynants, Patrick</creator><creator>Brichard, Vincent</creator><creator>Dréno, Brigitte</creator><creator>Tessier, Marie‐Hélène</creator><creator>Rankin, Elaine</creator><creator>Parmiani, Giorgio</creator><creator>Arienti, Flavio</creator><creator>Humblet, Yves</creator><creator>Bourlond, André</creator><creator>Vanwijck, Romain</creator><creator>Liénard, Danielle</creator><creator>Beauduin, Marc</creator><creator>Dietrich, Pierre‐Yves</creator><creator>Russo, Vincenzo</creator><creator>Kerger, Joseph</creator><creator>Masucci, Giuseppe</creator><creator>Jäger, Elke</creator><creator>De Greve, Jacques</creator><creator>Atzpodien, Jens</creator><creator>Brasseur, Francis</creator><creator>Coulie, Pierre G.</creator><creator>van der Bruggen, Pierre</creator><creator>Boon, Thierry</creator><general>John Wiley & Sons, Inc</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>19990118</creationdate><title>Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1</title><author>Marchand, Marie ; van Baren, Nicolas ; Weynants, Patrick ; Brichard, Vincent ; Dréno, Brigitte ; Tessier, Marie‐Hélène ; Rankin, Elaine ; Parmiani, Giorgio ; Arienti, Flavio ; Humblet, Yves ; Bourlond, André ; Vanwijck, Romain ; Liénard, Danielle ; Beauduin, Marc ; Dietrich, Pierre‐Yves ; Russo, Vincenzo ; Kerger, Joseph ; Masucci, Giuseppe ; Jäger, Elke ; De Greve, Jacques ; Atzpodien, Jens ; Brasseur, Francis ; Coulie, Pierre G. ; van der Bruggen, Pierre ; Boon, Thierry</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p3470-acc369c8ae2f29afa40e7c8648b67c3c11d8a97ca42715c988222d5b266ec6493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antigen Presentation</topic><topic>Antigens, Neoplasm - adverse effects</topic><topic>Antigens, Neoplasm - genetics</topic><topic>Antigens, Neoplasm - therapeutic use</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Genetic Code</topic><topic>HLA-A1 Antigen - immunology</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Melanoma - secondary</topic><topic>Melanoma - therapy</topic><topic>Middle Aged</topic><topic>Neoplasm Proteins - adverse effects</topic><topic>Neoplasm Proteins - genetics</topic><topic>Neoplasm Proteins - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Remission Induction - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Marchand, Marie</creatorcontrib><creatorcontrib>van Baren, Nicolas</creatorcontrib><creatorcontrib>Weynants, Patrick</creatorcontrib><creatorcontrib>Brichard, Vincent</creatorcontrib><creatorcontrib>Dréno, Brigitte</creatorcontrib><creatorcontrib>Tessier, Marie‐Hélène</creatorcontrib><creatorcontrib>Rankin, Elaine</creatorcontrib><creatorcontrib>Parmiani, Giorgio</creatorcontrib><creatorcontrib>Arienti, Flavio</creatorcontrib><creatorcontrib>Humblet, Yves</creatorcontrib><creatorcontrib>Bourlond, André</creatorcontrib><creatorcontrib>Vanwijck, Romain</creatorcontrib><creatorcontrib>Liénard, Danielle</creatorcontrib><creatorcontrib>Beauduin, Marc</creatorcontrib><creatorcontrib>Dietrich, Pierre‐Yves</creatorcontrib><creatorcontrib>Russo, Vincenzo</creatorcontrib><creatorcontrib>Kerger, Joseph</creatorcontrib><creatorcontrib>Masucci, Giuseppe</creatorcontrib><creatorcontrib>Jäger, Elke</creatorcontrib><creatorcontrib>De Greve, Jacques</creatorcontrib><creatorcontrib>Atzpodien, Jens</creatorcontrib><creatorcontrib>Brasseur, Francis</creatorcontrib><creatorcontrib>Coulie, Pierre G.</creatorcontrib><creatorcontrib>van der Bruggen, Pierre</creatorcontrib><creatorcontrib>Boon, Thierry</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>International journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Marchand, Marie</au><au>van Baren, Nicolas</au><au>Weynants, Patrick</au><au>Brichard, Vincent</au><au>Dréno, Brigitte</au><au>Tessier, Marie‐Hélène</au><au>Rankin, Elaine</au><au>Parmiani, Giorgio</au><au>Arienti, Flavio</au><au>Humblet, Yves</au><au>Bourlond, André</au><au>Vanwijck, Romain</au><au>Liénard, Danielle</au><au>Beauduin, Marc</au><au>Dietrich, Pierre‐Yves</au><au>Russo, Vincenzo</au><au>Kerger, Joseph</au><au>Masucci, Giuseppe</au><au>Jäger, Elke</au><au>De Greve, Jacques</au><au>Atzpodien, Jens</au><au>Brasseur, Francis</au><au>Coulie, Pierre G.</au><au>van der Bruggen, Pierre</au><au>Boon, Thierry</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1</atitle><jtitle>International journal of cancer</jtitle><addtitle>Int J Cancer</addtitle><date>1999-01-18</date><risdate>1999</risdate><volume>80</volume><issue>2</issue><spage>219</spage><epage>230</epage><pages>219-230</pages><issn>0020-7136</issn><eissn>1097-0215</eissn><coden>IJCNAW</coden><abstract>Thirty‐nine tumor‐bearing patients with metastatic melanoma were treated with 3 subcutaneous injections of the MAGE‐3.A1 peptide at monthly intervals. No significant toxicity was observed. Of the 25 patients who received the complete treatment, 7 displayed significant tumor regressions. All but one of these regressions involved cutaneous metastases. Three regressions were complete and 2 of these led to a disease‐free state, which persisted for more than 2 years after the beginning of treatment. No evidence for a cytolytic T lymphocyte (CTL) response was found in the blood of the 4 patients who were analyzed, including 2 who displayed complete tumor regression. Our results suggest that injection of the MAGE‐3.A1 peptide induced tumor regression in a significant number of the patients, even though no massive CTL response was produced. Int. J. Cancer 80:219–230, 1999. © 1999 Wiley‐Liss, Inc.</abstract><cop>New York</cop><pub>John Wiley & Sons, Inc</pub><pmid>9935203</pmid><doi>10.1002/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.0.CO;2-S</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0020-7136 |
| ispartof | International journal of cancer, 1999-01, Vol.80 (2), p.219-230 |
| issn | 0020-7136 1097-0215 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_17228030 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adult Aged Antigen Presentation Antigens, Neoplasm - adverse effects Antigens, Neoplasm - genetics Antigens, Neoplasm - therapeutic use Antineoplastic agents Biological and medical sciences Disease Progression Female Genetic Code HLA-A1 Antigen - immunology Humans Immunotherapy Male Medical sciences Melanoma - secondary Melanoma - therapy Middle Aged Neoplasm Proteins - adverse effects Neoplasm Proteins - genetics Neoplasm Proteins - therapeutic use Pharmacology. Drug treatments Remission Induction - methods |
| title | Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T16%3A14%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tumor%20regressions%20observed%20in%20patients%20with%20metastatic%20melanoma%20treated%20with%20an%20antigenic%20peptide%20encoded%20by%20gene%20MAGE%E2%80%903%20and%20presented%20by%20HLA%E2%80%90A1&rft.jtitle=International%20journal%20of%20cancer&rft.au=Marchand,%20Marie&rft.date=1999-01-18&rft.volume=80&rft.issue=2&rft.spage=219&rft.epage=230&rft.pages=219-230&rft.issn=0020-7136&rft.eissn=1097-0215&rft.coden=IJCNAW&rft_id=info:doi/10.1002/(SICI)1097-0215(19990118)80:2%3C219::AID-IJC10%3E3.0.CO;2-S&rft_dat=%3Cproquest_pubme%3E17228030%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17228030&rft_id=info:pmid/9935203&rfr_iscdi=true |